MaxCyte Valuation

Is MXCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MXCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MXCT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MXCT's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for MXCT?

Other financial metrics that can be useful for relative valuation.

MXCT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.5x
Enterprise Value/EBITDA-5.9x
PEG Ration/a

Price to Sales Ratio vs Peers

How does MXCT's PS Ratio compare to its peers?

The above table shows the PS ratio for MXCT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average5.1x
HVO hVIVO
2.8x4.7%UK£188.8m
ERGO Ergomed
4.6x8.8%UK£701.1m
DXRX Diaceutics
4.3x1.8%UK£112.4m
ONT Oxford Nanopore Technologies
8.5x22.6%UK£1.4b
MXCT MaxCyte
8.6x20.4%UK£299.1m

Price-To-Sales vs Peers: MXCT is expensive based on its Price-To-Sales Ratio (8.6x) compared to the peer average (5.2x).


Price to Earnings Ratio vs Industry

How does MXCT's PE Ratio compare vs other companies in the European Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.8%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.8%
n/an/an/a
No more companies

Price-To-Sales vs Industry: MXCT is expensive based on its Price-To-Sales Ratio (8.6x) compared to the European Life Sciences industry average (4.8x).


Price to Sales Ratio vs Fair Ratio

What is MXCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MXCT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.6x
Fair PS Ratio5x

Price-To-Sales vs Fair Ratio: MXCT is expensive based on its Price-To-Sales Ratio (8.6x) compared to the estimated Fair Price-To-Sales Ratio (5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MXCT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUK£2.84
UK£5.48
+93.1%
39.8%UK£7.67UK£3.30n/a2
Sep ’25UK£3.25
UK£5.48
+68.7%
39.8%UK£7.67UK£3.30n/a2
Aug ’25UK£3.60
UK£5.45
+51.4%
40.8%UK£7.67UK£3.23n/a2
Jul ’25UK£3.13
UK£5.47
+74.6%
40.1%UK£7.66UK£3.27n/a2
Jun ’25UK£3.70
UK£5.46
+47.6%
40.4%UK£7.67UK£3.25n/a2
Oct ’24UK£2.55
UK£7.39
+190.0%
6.5%UK£7.87UK£6.92UK£2.932
Sep ’24UK£2.93
UK£7.39
+152.8%
6.5%UK£7.87UK£6.92UK£3.252
Aug ’24UK£3.60
UK£8.43
+134.0%
7.0%UK£9.01UK£7.84UK£3.602
Jul ’24UK£3.50
UK£8.51
+143.1%
7.6%UK£9.15UK£7.86UK£3.132
Jun ’24UK£3.25
UK£8.52
+162.1%
7.8%UK£9.19UK£7.85UK£3.702
May ’24UK£3.85
UK£9.77
+153.7%
6.5%UK£10.40UK£9.13UK£2.952
Apr ’24UK£3.90
UK£9.77
+150.4%
6.5%UK£10.40UK£9.13UK£3.432
Mar ’24UK£3.88
UK£9.94
+156.4%
3.2%UK£10.25UK£9.62UK£3.732
Feb ’24UK£4.66
UK£9.94
+113.2%
3.2%UK£10.25UK£9.62UK£3.952
Jan ’24UK£4.38
UK£9.90
+126.3%
2.5%UK£10.15UK£9.65UK£3.532
Dec ’23UK£4.92
UK£10.04
+104.0%
3.6%UK£10.40UK£9.67UK£3.752
Nov ’23UK£6.00
UK£10.71
+78.5%
11.1%UK£11.90UK£9.53UK£2.452
Oct ’23UK£5.80
UK£10.71
+84.7%
11.1%UK£11.90UK£9.53UK£2.552

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies